Try our Advanced Search for more refined results
Life Sciences - November, 2020
330 articles
- Henry Thayer Co. Accused Of False 'Natural' Claims
- Judge Won't Quickly Pause Discovery In Shkreli's FTC Case
- 30 AGs Back $465M J&J Verdict In Landmark Opioid Trial
- Gov't Contracts Of The Month: Vaccines, Arms, Cloud Awards
- DoorDash Preps $2.6B IPO As December Blitz Gets Underway
- Bayer Hits Generic Co. With Another Hypertension Drug Suit
- PharMerica Beats Whistleblower's FCA Claims Over 'Swapping'
- Europe Hits Teva With €60M Fine Over Pay-For-Delay Deal
- Anticipating The Biden Administration's Health Care Agenda
- 7 Tips For Predeposition Meetings Under New Federal Rule
- AbbVie Gets Humira Kickbacks FCA Suit Limited To Florida
- How To Prepare For Congressional Investigations In 2021
- 11th Circ. OKs Sanctions Against Ex-Stryker Salesperson
- Coherus Loses Bid To Shift Fees To Amgen In Patent Suit
- Moderna Seeks FDA Approval For COVID-19 Vaccine
- Greenberg Traurig Taps Ex-HHS Atty For Health Care Practice
- Law360 Names Practice Groups Of The Year
- The Firms That Dominated In 2020
- DNA Sequencing Trial Wraps, Illumina Rival Seeks Invalidity
- Monsanto, BASF Get $265M Dicamba Verdict Slashed To $75M
- Zydus Insists Mitsubishi Doesn't Deserve Diabetes Patents
- EU Regulatory Plan Targets Big Pharma Competition, Mergers
- Appeals Court Says NJ Medical Pot Permit Scoring Is Flawed
- US, Smith & Nephew Urge Justices To Overturn Arthrex
- SmileDirect Tries To Save Calif. Dental Board Suit At 9th Circ.
- GAO Denies Protest Of Vaccine Research Contract
- Goodwin Steers Mass Spectrometry Biz Eyeing $75M IPO
- Coronavirus Regulations: A State-By-State Week In Review
- Sport Supplement Co., Owner Plead Guilty Over Steroids
- Suit Says 'Infant' Fever Drugs Are Same As 'Children' Drugs
- Ethics Reminders As Employees Move To Or From Gov't
- Telehealth Platform Can't Oust Medical Pot Co., Judge Says
- Groups Sue Trump To Block New Drug Import Rule
- Jury Awards $3.5M In Iowa Artificial Hip Trial
- Chancery Slams Gilead Stonewalling Over Records Demands
- No Discrimination Ban For Medical Pot Patients, Hospital Says
- HHS Says It's Working With Biden, Touts AstraZeneca Vaccine
- Mallinckrodt Ch. 11 Pauses Express Scripts Antitrust Claims
- NJ Cannabis Strides Highlight Nearby States' Need To Legalize
- EEOC Nabs $310K Recovery In Race, Sex Harassment Suits
- Surveying Drug Pricing Reform: The Latest State Activity
- Purdue Pleads Guilty In NJ To Criminal Opioid Conspiracy
- Biomet To Pay $21M In Hip Implant Defect Suit Verdict
- Don't Fear IP-Antitrust 'Turducken' In Reverse-Payment Cases
- How Joe Biden Will Change The FDA: Part 2
- Pa. Retailers Accused Of Wrongly Charging Tax On Masks
- USPTO Aims To End Tech Giants' PTAB Denials Challenge
- UK Antitrust Arm Mulling Bipolar Drug Co.'s Commitments
- A Key To Helping Clients Make Better Decisions During Crisis
- Greenberg Traurig Clears Conflict Inquiry In $1B Fraud Case
- Teva's Bid To Duck MDL Trials Slammed As 'Fool's Errand'
- Biotech Co. Defeats Investor Suit Over Short-Seller Reports
- Supplier Sued Over $5.4M In FDA-Barred Sanitizer Wipes
- Fed. Circ. Affirms Hospira's Generic Adrenalin Loss To Par
- Abbott Labs Fights Amended ERISA Claims Over Stolen $245K
- AstraZeneca Finds 90% Vaccine Success, Will Seek Approval
- Merck Again Denied In Bid To Arbitrate Vaccine Antitrust Suit
- HHS Increasing IP License Transparency After GAO Rebuke
- Stericycle Investor Seeks Atty Sanction After Objector Claim
- Texas Law Firm, Mexican Supplier Settle $3M Mask Sale Row
- Latham-Led Life Sciences Co. Debuts With $800M In Backing
- Retailers Accuse Pharma Cos. Of Blocking Generic Bystolic
- How Joe Biden Will Change The FDA: Part 1
- 1st Circ. Backs Convictions For Pharma Inside Traders
- A Forgotten But Effective Tool Against Opioid Scams
- Ethics Considerations For Law Firms Implementing AI
- Feds Say No Privilege For Ex-Theranos CEO In Fraud Case
- Trump Slams Big Pharma In Rollout Of Drug Price Rules
- FDA Targets COVID-19 Claims Over Stem Cell, Dental Products
- Medical Marijuana Co. Sues Law Firm For Malpractice
- WTO Divided Over Suspending Protection Of COVID-19 IP
- Hospital Looks To Block Plan To Boot It From Health Network
- Judge Gives Initial OK To Correvio Pharma $1.75M Class Deal
- Pot Co. Liberty Health Agrees To Settle $1.8M Securities Row
- Pfizer, BioNTech Seek Emergency COVID-19 Vaccine Approval
- Pair Of Health-Focused Cos. Tap Market For $2.7B Via IPOs
- Mallinckrodt Can Use Lender Cash As Ch. 11 Probe Proceeds
- When A Product Liability Case Can't Survive Outside An MDL
- 7th Circ. Backs Ex-Pharma Head's Nearly 3-Year Sentence
- J&J Unit, PE Firm To Pay $11.5M Over FCA Claims
- AstraZeneca Affiliates Duck $275M Merger Payment Suit
- How Federal Virus Liability Law Will Apply To Vaccine Claims
- Health Hires: Epstein Becker, Lewis Brisbois, Taylor English
- UK Litigation Roundup: Here's What You Missed In London
- Picking The Right Location And Tools For Virtual Courtrooms
- Contractor Fights Investors' Claims Over COVID Test Kit Deal
- What To Expect From The USPTO In The Biden Administration
- White House, CDC Call For Vigilance Amid COVID-19 Surge
- Pot Co. Defeats Accountant's Wrongful Termination Claim
- Cannabis Biz Ayr Buys Pa. Medical Pot Grower For $21M
- LinkedIn, Zynga Founders' SPAC Leads 4 Raising $530M Total
- China Biologic Lands $4.76B Value In Take-Private Deal
- Anthem Adds Ex-HCSC Atty As Its General Counsel
- Hospital Can't Escape Suit Over Surgery With Recalled Laser
- Utah Medical Pot Licensing Marred By Bias, Auditor Says
- Coronavirus Litigation: The Week In Review
- 5 Red Flags For Pandemic-Related Investment Scams
- Fed. Circ. Affirms $107M Inhaler IP Judgment Against GSK
- Teva Inks $2.55M Deal To Settle 401(k) Fee Suit
- Beware Atty Ethics Rules When Reporting COVID-19 Fraud
- Latham-Led REIT Lands $1.7B For Life Science Projects
- AmerisourceBergen Held In Contempt In Wash. Opioid Suit
- MiMedx Execs Convicted In SDNY's 1st Virus-Era Fraud Trial
- COVID-19 Tort Cases Aimed Largely At Cruise Lines
- Prof Wins $8M IP Trial Against Health Cos., Convicted Ex-Atty
- Judge Refuses To Halt Biomet Trial After Juror Caught Virus
- Fla. Judge OKs Prevagen Deal After Striking Objection
- Feds Urge Court Not To Ax $300M Teva Kickback Case
- Mallinckrodt Says Order Gives Time For Transfer Probes
- Pa. Appeals Court OKs Benefits For Fired Medical Pot User
- Trump Admin. Touts COVID-19 Vaccine Success, Preps Rollout
- HHS Cancels $15M Celebrity-Filled Virus Campaign After Audit
- Judge Unlikely To Toss Fight Over COVID-19 Biz's Soured Deal
- Ecolab Says Ex-Manager's Rival Biz Used Trade Secrets
- Jury Mulls Fraud Case Against Ex-MiMedx Execs For 3rd Day
- Looking For Judicial Activists? Check The Footnotes
- Ill. City Says Mallinckrodt Ch. 11 Can't Halt Antitrust Claims
- Courts Are Not Confused About Opioid Insurance Suits
- House OKs Bill To Join Global Health Org. Funding Vaccines
- Using Prior Art In Patentability Args Amid Fed. Circ. Confusion
- Best Practices For Legal Technology Adoption
- Del. Judge Pushed Trial Due To Spoliation Claim, Not Virus
- Real Estate Rumors: IQHQ, Longfellow, PulteGroup
- Valuation Uncertainty Could Prompt Increased Litigation
- Judge Strikes Opioid Claims Against Prescribers
- KKR Takes $100M Ownership Stake In NZ Animal Health Co.
- Former Insys Execs Win Another COVID-19 Prison Delay
- Purdue Pharma Gets Court Approval For $8B Deal With Feds
- Abbott Must Face Patent Suit Over Baby Probiotics
- House Passes Bill Targeting Orphan Drug Exclusivity
- Pot Retailers Harvest And Vireo Sell Off Assets In 2 States
- FDA Answers GAO Calls For COVID-19 Vaccine Transparency
- Zetia Buyers Spar With Merck, Glenmark Over Expert Witness
- Amgen, GSK Urge Justices To Allow Patents On Genus Claims
- Fed. Circ. Ruling May Reshape Hatch-Waxman Litigation Map
- FTC Urges 3rd Circ. To Restore $448M AbbVie Penalty
- Wilson Sonsini Scores Ex-New York Antitrust Chief
- Miss. High Court Takes Up Challenge To Medical Pot Measure
- House Passes Bipartisan Bills To Fight Opioid Crisis
- Coronavirus Regulations: A State-By-State Week In Review
- The Pandemic's Long-Term Impact On Law Firm Operations
- How Biden Might Dismantle Trump-Era Regulations
- Cannabis In NJ Can't Work Without Medical Marketplace Fix
- Exec Pleads Guilty, Will Pay $16.5M For Medicare Fraud
- Missing Inventor Doomed Broad's CRISPR Patent At EPO
- 4th Circ. Will Fast-Track Challenge To Zetia Buyers' Class Cert.
- Rejected NJ Pot License Applicants Press AG For Settlement
- Illumina Wants Calif. Court To Double $27M IP Win Over Roche
- 14 Firms To Steer 10 IPOs In Pre-Thanksgiving Rush
- Jury Mulls Case Against Ex-Execs As SDNY Navigates Virus
- USPTO Defends Ax Of Nutrition Supplement IP To Justices
- Ex-HHS Atty Joins McDermott At Key Time For Health Care
- Terns Pharmaceuticals Brings On New Top Lawyer
- Lack Of Access To Remote Court Proceedings Is Inexcusable
- Imerys Gets Nod For $223M Ch. 11 Sale; $30M Loan Delayed
- Feds Say $225M Sackler Fine To Go To Medicare, Medicaid
- In Fraud Alert, HHS Watchdog Urges End To Pharma Events
- DHS Flags Becton Medical Pump For Cybersecurity Issues
- ViSalus Says Lack Of Harm Dooms $925M Robocall Award
- Biogen Investors Say Co. Misled Them On Alzheimer's Drug
- Criminal Charges Should Delay Hemp Dispute, Calif. Says
- Chinese Co.'s US Unit May Get Access To Virus-Testing Patent
- Russia, North Korea Accused Of Hacking Vaccine Research
- Manufacturer Must Face Suit Over Worker's Biometric Data
- Health Org Gets $2B To Give Poor Nations COVID-19 Vaccines
- Another Dem Raises Concerns Over $1B Virus Fund Spending
- 3 Firms Score End-Payor Co-Lead Role In Seroquel XR Cases
- Opioid Expert's Data Belongs In Bellwether Trial, Judge Told
- Why Attacks On Trump's Election Lawyers Are Problematic
- Health Hires: Cozen O'Connor, LumiThera
- FDA, DEA Experts Cleared To Testify In NY AG's Opioid Case
- FDA Must Address Lannett's Lies On Cocaine Drug, Suit Says
- Top WTO Official Wants Tariffs On Medical Supplies Dropped
- Vaccine Developers Must Put Cure Before Patent Profits
- Insulin Pen Buyers Say Sanofi Antitrust Suit Not Overly Broad
- Purdue's $8B Deal Doesn't End Calif.'s Row With Big Pharma
- Coronavirus Litigation: The Week In Review
- Ex-Insys Exec Who Flipped Seeks COVID-19 Prison Delay
- Sanofi Must Face Cancer Drug FCA Claims At Trial
- Supreme Court Urged To Make Arbitration Contracts Binding
- InfoBionic Tells Justices Patent Eligibility Is 'Off The Rails'
- States Say $8.3B Purdue Opioid Deal Flouts Bankruptcy Rules
- Kodak Says Ex-Execs Made $5.1M On Forfeited Stock Options
- State Pot Regulators Join Forces To Share Best Practices
- Justices Told Not To Revisit $268M Hearing Aid Patent Award
- Zetia Buyers Seek To Speed Up Drug Cos.' Class Cert. Appeal
- Avoiding 6 Common E-Discovery Production Pitfalls
- Cleary Steers PE-Backed Sotera Health's $1B IPO Launch
- What To Expect From US Trade Policy In The Biden Era
- Researcher Cops To Hiding China Ties To Win $4M In Grants
- Verano, AltMed Merger Creates Privately Held Pot Giant
- PTAB Mylan Decision Could Be Boon To Drug Innovators
- New Vivus Ch. 11 Plan Offers Stockholders Drug Royalties
- Shkreli's Objections To FTC Prison Comms Access Tossed
- Pfizer Unit Hit With Another Suit Over Tossed Lyrica Patent
- Biden Taps BigLaw Partner, Obama Officials For HHS Review
- Bard Gets Fed. Circ. To Revive $68M Infringement Trial
- 4 Key Moments As Justices Debate ACA's Fate
- GSK Says FDA Rejected Zofran Label Change
- FTC Probes Illumina's $8B Deal For Cancer Detection Biz
- Fed. Circ. Remands Ferring Drug Patent Inventorship Fight
- Pot Co. Seeks High Court Review Of IRS Summons Fight
- Rival Accuses ProMedica Of Anti-Competitive Conduct
- CVS, Rite Aid Say Doctors Also Liable For Prescribing Opioids
- Sterigenics' Suit Over Ga. Plant Shutdown Kept Alive For Now
- Coronavirus Regulations: A State-By-State Week In Review
- Drug Price Checker's Legality Mulled Amid Bid To Toss Suit
- Boehringer To Settle 3K Pradaxa Bleeding Risk Cases
- Citing 'Botox,' TTAB Rejects 'Boto Smart' Trademark
- SEC Wants $15M From Sanofi Insider Trading Suspect
- Edwards Lifesciences Bolsters Tech's Attack On PTAB Denials
- West Pharmaceutical Hires Segal Group GC
- Feds To Take True Health Ch. 11 Plan Appeal To 3rd Circ.
- DEA Hemp Rule Could Lose Edge Under Biden Admin.
- Substantive Issues Plague China's Patent Linkage Regime
- Law Firm Biz Development Tips For The Pandemic Era
- ACA Likely To Survive High Court Ruling On Mandate
- Allied BioScience Says Founder, Ex-CEO Holding IP Hostage
- 4 Key Developments As US Coronavirus Cases Hit 10M
- 9th Circ. Urged To Nix Private Commercial Arbitration Doc Bid
- Grocer Secures Defense Coverage In Opioid Injury Suits
- Chancery Won't Pause Vaxart Insider-Trading Suit In Del.
- Muscogee (Creek) Nation Passes Post-McGirt Marijuana Law
- McKesson Says Ex-Exec's Opioid Guilty Plea Is Inadmissible
- 3M Wins Trial Over Ship Worker's Faulty Respirator Claims
- Customedia Calls For 2nd Shot After Justices Take Up Arthrex
- Biosimilars Caught In Crosshairs Of Supreme Court ACA Fight
- Justices Snub 2 Post-Arthrex Cases, Seek Reply In Another
- Biotech Co. Investors Battle To Lead COVID-19 Vaccine Suit
- Goodwin Procter Guides Biopharma Co.'s $50M IPO Plans
- Texas Law Firm Launches Counterclaims In Mask Sale Fight
- Snell Seeks Sanctions For Ex-NFL Player In Liability Fight
- Dentist's Virus Suit Returned To State Court Despite Protest
- Rulings Show Limits Of Federal Agency Vacancy Law
- Zoll Medical Sues Security Co. Over Major 2018 Data Breach
- Illumina Says Rival Infringes DNA Sequencing IP At Trial Start
- AbbVie Takes Takeda To Chancery Over Lupron Shortfall
- Arsenic, Toxins In Apple Juice Sent To Schools, FDA Says
- What You Need To Know About Biden And IP
- Biden Opioid Plan Puts Pharmacies On Notice
- 5 Key Areas To Watch As 'Bidencare' Takes Shape
- Biden Win May Lead To First Black Female Justice
- High Court Expansion Unlikely After Tight Election
- Biden's Win Means Big Business For BigLaw
- Biden Beats Trump At The Polls As Court Battles Continue
- FDA Panel Won't Back Approval Of Biogen's Alzheimer's Drug
- Becton Says Revived Antitrust Suit Should Be Axed For Good
- 2 Firms Guide REIT, GIC Launch Of JV With $930M Projects
- FDA Must Face Trial In Ex-Worker's Sex Harassment Suit
- PTAB Again Upholds Pfizer Pneumonia Vaccine Patent Claim
- SEC Expands Pfizer Bribery Inquiries Into China
- HHS Opinions Signal Broad Immunity From COVID-19 Liability
- Patent Filings Dropped As Pandemic Gripped US
- Curaleaf To Fund Maryland Growth With $31.5M Pot Asset Sale
- Meet The Attys Arguing ACA's Fate At Supreme Court
- 3 Firms Build Novo Nordisk's $1.8B Emisphere Buy
- Servier Loses Bid To Enforce EU Pay-For-Delay Ruling In UK
- $26B Opioid Deal Offer To Include $2B In Atty Fees
- Testimony In NJ Zoom Trial Wraps In Diabetes Drug IP Row
- Online Pharmacy, Ex-Exec Sue Polsinelli Over SEC Probe Fees
- Inovio Defends Virus Vaccine Claims In Bid To Nix Stock Suit
- Ex-Startup CEO Gets 135 Months For Embezzling $3M
- 4 Things To Know About China's Revised Patent Law
- Fed. Circ. Restricts Venue Options For Hatch-Waxman Suits
- Coronavirus Litigation: The Week In Review
- FDA Must Study Enviro Risks Of Genetically Engineered Fish
- BigLaw Must Drop The Billable Hour To Improve Diversity
- 10th Circ. IRS Summons Ruling Shows Cannabis Biz Dilemma
- Medical Pot Co. Claims Franchisee Sold Bootleg Products
- Medical Pot Biz Vireo Inks Debt Deal Worth Up To $46M
- Merck Plows Ahead With Another Suit Over Diabetes Drug
- Aviation Insurers Must Prep For Vaccine Shipment Risks
- Allergan Can Sue Pfizer To Recoup Opioid Litigation Costs
- Actavis Can't Escape Testosterone Drug Warning Claims
- 3 Bankruptcy Rulings Highlight Barriers For Pot-Adjacent Cos.
- Gibson, Cooley Craft Merck's $2.75B Cancer Therapy Co. Buy
- HHS Floats Plan To 'Sunset' Unnecessary Regulations
- Full Fed. Circ. Won't Reconsider Bio-Rad's $24M IP Verdict
- J&J Slams Imerys' Objection To $20M Claim In Ch. 11 Case
- Merck Says Pfizer's Trade Secrets Counterclaims Are Useless
- Trump Unleashes Barrage Of Lawsuits In Battleground States
- Fla. Biotech Cuts Deal To Develop COVID-19 Vaccine In China
- UnitedHealth Beats Labs' $49M ERISA Suit Over Claim Denials
- Pot's Ballot Victories Bode Well For Reform's Future
- Irish Court Rejects Perrigo's Bid To Quash $1.92B Tax Bill
- Biomet Orthopedics Can't Duck Defective Hip Implant Suit
- McKesson Whistleblowers Fight Bid To Toss Opioid FCA Suit
- Cannabis Biz EMMAC's Blank-Check Deal Falls Through
- Amgen Biosimilar Rows Reveal Manufacturing Patents' Value
- Fed. Circ. Urged To Restore Narcan Patents
- Mont. Voters Approve Measure To Legalize, Tax Marijuana
- South Dakota Voters Pass Pot Legalization Initiative
- Senate Majority Still In Doubt As Races Tighten
- Biden Campaign Plays Down Trump High Court Threat
- Trump Vows To Contest Uncounted Ballots At High Court
- The BigLaw Attorneys Battling Over An Undecided Election
- Don't Look To Bush v. Gore For 2020 Blueprint
- Senate — And Pandemic Relief — Still Hanging In The Balance
- New Jersey, Ariz. Legalize Pot In Ballot Measure Sweep
- Miss. Voters Approve Citizen-Led Medical Marijuana Initiative
- Ore. Voters OK Legalizing Psychedelic Mushroom Substance
- Gilead Says Homeless Recruited To Scam HIV Drug Charity
- NJ Voters Approve Pot Legalization At Ballot
- Generics Cos. Attack 'Serial' Complaints In Price-Fixing Row
- Online Talc Jury Trial Against J&J Ends In Mistrial
- Gov't Entities Seek Probe Of $1B Mallinckrodt Debt Swap
- Coronavirus Regulations: A State-By-State Week In Review
- McKesson, 2 Other Distributors Ink $21B Opioid Settlement
- 4th Circ. Says OK To Zetia Class Certification Challenge
- 3rd Circ. Tosses Defect Claims Over Abbott Artery Device
- Compliance Lessons From DOJ's Merit Medical Settlement
- Bayer Budgets $2B To Settle Future Roundup Cancer Claims
- FTC OKs Stryker's $4B Wright Medical Deal, With Divestitures
- Red States Back FDA Limits On Abortion Pills At 4th Circ.
- Mo. High Court Won't Review $2.1B J&J Talc Verdict
- Fed. Circ. Rejects Email-Deleting Glaucoma Co.'s Plea
- 8 Tips For Effective Oral Advocacy In Virtual Court Hearings
- From The Front Lines: The Attorneys Protecting This Election
- W.Va. Gov'ts Rip Bid To Block Opioid Victims' Testimony
- Guardant Patent Trial Delayed After Virus Safety Objections
- Insys Founder Wants Another Prison Delay Due To COVID-19
- Trump Admin. Expands Efforts To Keep Opioids Out Of US
- AbbVie Wants Hypertension Drug Antitrust Row Sent To NJ
- Justices Skip Case Horizon Said Puts 32K Patents At Risk
- Professor Says Parkinson's Cure Fight Belongs In California
- Abbott Wins Order Barring Ex-Exec From Sharing Virus Info
- Growth And Challenges For Life Sciences CRE Amid COVID-19
- Trump Admin. Sued Over Inadequate COVID-19 Reporting
- Boehringer Accused Of Withholding Royalties As Trial Starts
- A GC's Blueprint For Improving Legal Industry Diversity